plerixafor has been researched along with Multiple Myeloma in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (11.56) | 29.6817 |
| 2010's | 115 (78.23) | 24.3611 |
| 2020's | 15 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Aoki, K; Kohno, K; Nishimura, N; Obara, T; Ogawa, R; Okamura, K; Taenaka, R; Takigawa, K | 1 |
| Arai, Y; Ishii, A; Jo, T; Kanda, J; Kitawaki, T; Matsui, K; Nagao, M; Nakagawa, Y; Niwa, N; Oshima, S; Takaori-Kondo, A | 1 |
| Alexander, MD; Bucci, TG; Chen, KY; Grgic, T; Ptachcinski, JR; Riches, M; Shaw, JR | 1 |
| Bhella, S; Dehghani, M; Hopman, W; Yang, C | 1 |
| Badros, AZ; Hardy, N; Kocoglu, M; Rapoport, AP; Rybinski, B | 1 |
| Crawford, B; Iida, S; Ishida, T; Kanamori, R; Miyamoto, T; Shirai, H; Tajima, Y; Teramukai, S; Teshima, T; Yi, J | 1 |
| Anderson, KC; Armand, P; Azab, AK; Basile, F; Baz, R; Boruchov, A; Chuma, S; Constantine, M; Crilley, P; Ghobrial, IM; Henrick, PM; Hornburg, KTV; Laubach, JP; Leblebjian, H; Liu, CJ; Mishima, Y; Munshi, NC; Noonan, K; Paba-Prada, C; Reyes, K; Richardson, PG; Schlossman, R; Shain, K; Trippa, L; Vredenburgh, J; Warren, D; Weller, E; Zavidij, O | 1 |
| Auner, HW; Basak, GW; Celanovic, M; Chabannon, C; Garderet, L; Hayden, P; Iacobelli, S; Knol, C; Kobbe, G; Krejci, M; Kröger, N; Lenhoff, S; Liu, Q; Masszi, T; Morris, C; Nahi, H; Pohlreich, D; Russell, N; Schaap, N; van Biezen, A | 1 |
| Alvarado-Navarro, DM; Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Del Carmen Tarín-Arzaga, L; Flores-Jiménez, JA; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; León, AG; Mejía-Jaramillo, G; Palomares-Leal, A; Salazar-Riojas, R; Sotomayor-Duque, G | 1 |
| Alavi, A; Ayash, L; Deol, A; Kim, S; Ratanatharathorn, V; Shah, H; Singh, P; Uberti, J | 1 |
| Damon, LE; Leavitt, AD; Loeffler, P; Martin, TG; Shah, EE; Shah, ND; Wolf, JL; Wong, SW; Young, RP | 1 |
| Bakeer, M; Roy, V; Zubair, AC | 1 |
| Avalon, M; Bijou, F; Brunet de la Grange, P; Cabantous, T; Debeissat, C; Duchez, P; Ivanovic, Z; Mombled, M; Pasquet, JM; Pérard, B; Rodriguez, L; Sawai, KM; Thévenot, F; Vlaski-Lafarge, M | 1 |
| Fitzhugh, C; Hankins, JS; Hauffe, S; Hsieh, M; Hughes, TE; Leonard, A; Molloy, E; Panch, SR; Sharma, A; Stroncek, D; Taylor, T; Tisdale, JF; Tsai, SQ; Uchida, N; Weiss, MJ; West, K; Wilson, M | 1 |
| Araki, Y; Furuta, Y; Komatsu, N; Miyake, K; Nakamura, Y; Noguchi, M; Ohsaka, A; Okubo, M; Osawa, T; Sawada, T; Sekiguchi, Y; Tada, N; Yamatoya, K | 1 |
| Dou, XL; Duan, WB; Huang, XJ; Lei, L; Lu, J; Wang, FR | 1 |
| Gawroński, K; Rzepecki, P; Sawicki, W; Wajs, J | 1 |
| Bonifazi, F; Bosi, A; Cascavilla, N; Cellini, C; Lanza, F; Laszlo, D; Martino, M; Musto, P; Pezzi, A; Saraceni, F; Tani, M; Zuffa, E | 1 |
| Azab, AK; Chatterjee, M; Decker, S; Duyster, J; Engelhardt, M; Follo, M; Ihorst, G; Lorenz, J; Müller, SJ; Simon, A; Waldschmidt, JM; Wäsch, R; Wider, D | 1 |
| Bosse, R; Duyster, J; Engelhardt, M; Greil, C; Hildenbeutel, S; Ihorst, G; Kiote-Schmidt, C; Kühbach, K; Wäsch, R | 1 |
| Apperley, J; Blaise, D; Browne, P; Garderet, L; Iacobelli, S; Isaksson, C; Kobbe, G; Koster, L; Krejci, M; Kröger, N; Lenhoff, S; Ljungman, P; Morris, C; Muñiz, SG; Reményi, P; Russell, NH; Sahebi, F; Sanchez, JF; Sbianchi, G; Schaap, N; Scheid, C; Schönland, S; Trneny, M; Wiktor-Jedrzejczak, W; Wilson, KMO; Yakoub-Agha, I | 1 |
| Bolwell, B; Cheverton, PD; DiPersio, JF; Horwitz, ME; Kaufman, JL; Maziarz, RT; McCarty, JM; Micallef, IN; Nademanee, AP; Stadtmauer, EA; Stiff, PJ; Struijs, M; Vargo, R | 1 |
| Kayamori, K; Kuwabara, C; Shimizu, R; Suzuki, Y; Tanaka, H | 1 |
| Celanovic, M; Liu, Q; Lund, J; Nahi, H; Peceliunas, V | 1 |
| Arora, S; Liu, H; Majhail, NS | 1 |
| Ali, N; Beck, R; Covut, F; de Lima, M; Dosani, T; Downes, K; Fox, R; Kim, BG; Maitta, R; Malek, E; Pinto, R; Reese, J | 1 |
| Adachi, H; Akiyama, M; Doki, N; Fujita, M; Igarashi, A; Inamoto, K; Kaito, S; Kakihana, K; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Kumagai, T; Nagata, A; Najima, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y; Yoshifuji, K | 1 |
| Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N | 1 |
| Farol, L; Forman, SJ; Htut, M; Krishnan, AY; Palmer, JM; Thomas, SH; Tsai, NC; Wang, S | 1 |
| Awan, F; Craig, M; Cumpston, A; Deremer, D; Falconer, DE; Hamadani, M; Jillella, A; Kochuparambil, ST; Leadmon, S; Watkins, K | 1 |
| Kogut, N; Krishnan, A; Nademanee, A; Shayani, S; Wang, S; Yuan, S | 1 |
| Carlo-Stella, C; Corradini, P; Dodero, A; Farina, L; Guidetti, A; Longoni, P; Montefusco, V; Ravagnani, F; Spina, F | 1 |
| Abdel-Rahman, F; Al Rawi, O; Hussein, A; Hussein, N; Jazar, HA; Saad, A; Sharma, S; Tuffaha, HW | 1 |
| Alousi, A; Anderlini, P; Champlin, R; Ciurea, S; de Lima, M; Hosing, C; Kebriaei, P; Khouri, I; Nieto, Y; Popat, U; Qazilbash, M; Rondon, G; Smith, VR | 1 |
| Flowers, CR; Harvey, RD; Johnson, HR; Kaufman, JL; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; Nooka, A; Vaughn, L; Waller, EK | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Bosi, A; Cascavilla, N; Guggiari, E; Imola, M; Lanza, F; Laszlo, D; Lemoli, RM; Martinelli, G; Martino, M; Milone, G; Olivieri, A; Pasini, A; Pavone, V; Rambaldi, A; Scortechini, I; Specchia, G; Todisco, E | 1 |
| Bilgin, YM; Croockewit, A; de Greef, GE; Gahar, RR; Visser, O | 1 |
| Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ | 1 |
| Kořístek, Z; Lysák, D; Tichopád, A; Vítová, V | 1 |
| Isola, LM; Miller, LK; Shi, PA | 1 |
| Cupri, A; Di Marco, A; Di Martina, V; Leotta, S; Martino, M; Milone, G; Scalzulli, P; Schinocca, E; Spadaro, A; Spina, E; Tripepi, G | 1 |
| Bensinger, W; Copelan, E; Costa, L; Devine, S; Dipersio, J; Giralt, S; Hosing, C; Leather, H; Maziarz, R; McCarty, J; Negrin, R; Pazzalia, A; Petersen, FB; Rondelli, D; Schriber, J; Shaughnessy, P; Snyder, E; Soiffer, R | 1 |
| Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL | 1 |
| Chang, CC; Choi, DS; Jiang, B; Su, J; Wen, J; Zhang, L; Zhang, W; Zhou, X | 1 |
| Bruckner, T; Engelhardt, M; Goldschmidt, H; Ho, AD; Hundemer, M; Kraeker, S; Neben, K; Sauer, S; Schmitt, A; Witzens-Harig, M; Wuchter, P | 1 |
| Baerlocher, GM; Friess, D; Keller, P; Leibundgut, K; Mansouri Taleghani, B; Mueller, BU; Pabst, T; Schmid, A | 1 |
| Came, N; Demosthenous, L; Harrison, S; Herbert, KE; Link, E; Prince, HM; Ritchie, DS; Seymour, JF; Westerman, DA; Wiesner, G | 1 |
| Banoff, K; Isola, L; Kim, SS; Renteria, AS; Steinberg, A | 1 |
| Budisavljevic, MN; Butcher, C; Chhabra, S; Costa, LJ; Edwards, KH; Kang, Y; Kramer, C; Littleton, A; Schade, H; Schneider, M; Stuart, RK | 1 |
| Cohen, AD; Dougherty, AL; Garfall, AL; Mick, R; O'Doherty, U; Stadtmauer, EA; Vogl, DT; Weiss, BM | 1 |
| Alexi, R; Buss, EC; Chen, BA; Cheng, J; Goldschmidt, H; Hillengass, J; Ho, AD; Hundemer, M; Neben, K; Schmitt, A; Schmitt, M; Witzens-Harig, M; Wuchter, P | 1 |
| Jang, JH; Jung, CW; Jung, SK; Kang, ES; Kim, DW; Kim, K; Kim, SJ; Kim, WS; Lee, KH | 1 |
| Barba, P; Duarte, RF; Encuentra, M; Esquirol, A; Garcia-Cerecedo, T; Grifols, JR; Martí, JM; Ortega, S; Pujol-Balaguer, MM; Pujol-Bosch, M; Querol, S; Sánchez-Ortega, I; Sanchez-Villegas, JM; Sancho, JM; Serra, A; Sierra, J | 1 |
| André, M; Baily, L; Dierickx, D; Huyngh, P; Lambert, C; Noens, L; Selleslag, D; Van de Velde, A; Willems, E; Zachee, P | 1 |
| Gardellini, A; Lanza, F; Laszlo, D; Martino, M | 1 |
| Bell, J; Braithwaite, B; Callaghan, T; Clark, JO; Clark, RE; Francis, S; McGinnity, N; Salim, R; Vithanarachchi, U | 1 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Arabi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Talhi, S; Yafour, N | 1 |
| Beckers, EA; Bilgin, YM; Croockewit, AJ; de Greef, GE; Huisman, C; Kramer, EP; Netelenbos, T; te Boome, LC; Visser, O; Ypma, PF | 1 |
| Antar, A; Bazarbachi, A; Ghaddara, HA; Kharfan-Dabaja, MA; Kreidieh, N; Mahfouz, R; Otrock, ZK | 1 |
| Bachier, C; Elayan, MM; Horowitz, JG; Magraner, JM; Shaughnessy, PJ | 1 |
| Bao, M; Guan, Y; Guo, R; Li, X; Wang, Y; Wu, A; Xie, F; Yue, Y; Zhang, C | 1 |
| Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK | 1 |
| Bell, J; Braithwaite, B; Clark, JO; Clark, RE; Haycox, A; Houten, R; Martin, AP; McLeod, C; Richards, S | 1 |
| Craig, M; Cumpston, A; Hamadani, M; Kanate, AS; Leadmon, S; Luo, J; Shillingburg, A; Veltri, L; Watkins, K; Wen, S | 1 |
| Engert, A; Hartmann, T; Hübel, K; Monsef, I; Skoetz, N | 1 |
| Adel, NG; Afifi, S; Chung, DJ; Devlin, S; Duck, E; Giralt, S; Hassoun, H; Korde, N; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Reich, L; Vanak, J | 1 |
| Cho, SG; Do, YR; Eom, HS; Kim, H; Kim, JS; Kim, WS; Kwak, JY; Lee, J; Lee, JJ; Min, CK; Moon, JH; Park, S; Suh, C; Yang, DH; Yoon, DH; Yoon, SS | 1 |
| Motalkina, MS | 1 |
| Baker, J; Cooper, DL; Foss, F; Medoff, E; Patel, N; Perreault, S; Pratt, K; Seropian, SE; Wu, Y | 1 |
| Jantunen, E; Valtola, J; Varmavuo, V | 1 |
| Duarte, R; Marín, P; Medina, L; Querol, S; Sancho, JM; Sureda, A | 1 |
| Ahonen, J; Anttila, P; Jantunen, E; Mahlamäki, E; Mäntymaa, P; Putkonen, M; Remes, K; Säily, M; Sankelo, M; Savolainen, ER; Silvennoinen, R; Varmavuo, V | 1 |
| Götze, K; Krackhardt, AM; Peschel, C; Peter, R; Spoerl, S; Verbeek, M; Wäscher, D | 1 |
| Calandra, G; MacFarland, R; Smith, C; Stewart, DA | 1 |
| Alt, C; Anderson, KC; Azab, AK; Azab, F; Burwick, N; Carlson, AL; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Kung, AL; Leleu, X; Lin, CP; Melhem, MR; Moreau, AS; Munshi, NC; Ngo, HT; Ospina, B; Pitsillides, C; Roccaro, AM; Rollins, BJ; Runnels, JM; Sacco, A; Wright, R | 1 |
| De Clercq, E | 1 |
| Badel, K; Calandra, G; Magalhaes-Silverman, M; McCarthy, P; Micallef, I; Stiff, P; Territo, M; Weisdorf, D | 1 |
| DiPersio, JF; Kirkpatrick, P; Uy, GL; Yasothan, U | 1 |
| Wagstaff, AJ | 1 |
| Bridger, G; Calandra, G; Cooper, D; DiPersio, JF; Früehauf, S; Horwitz, M; Hosing, C; Kaufman, JL; Maziarz, RT; Micallef, IN; Nademanee, A; Stadtmauer, EA; Stiff, PJ | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Badel, K; Bensinger, WI; Bridger, G; Calandra, G; Dehner, C; Dugan, MJ; Gibney, C; Liesveld, J; Maziarz, RT; Nademanee, A | 1 |
| Anderson, KC; Attal, M; Barlogie, B; Bensinger, W; Blade, J; Boccadoro, M; Cavo, M; Chen, W; Comenzo, RL; Dimopoulos, MA; Dispenzieri, A; Durie, BG; Einsele, H; Gertz, M; Giralt, S; Hajek, R; Harousseau, JL; Jagannath, S; Joshua, D; Kumar, S; Kyle, R; Lonial, S; Ludwig, H; Mateos, MV; Merlini, G; Morgan, G; Munshi, NC; Niesvizky, R; Palumbo, A; Powles, R; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Stadtmauer, EA; Tosi, P; Turesson, I | 1 |
| Badel, K; Calandra, G; Ehninger, G; Fruehauf, S; Goldschmidt, H; Ho, AD; Hübel, K; Moos, M; Müller, S; Topaly, J | 1 |
| Gaarsdal, E; Hansen, PB | 1 |
| Choi, HY; Yong, CS; Yoo, BK | 1 |
| Badel, K; Calandra, G; Comenzo, RL; Flomenberg, N | 1 |
| Chang, CC; Choi, DS; Eshoa, C; Feng, Y; Mike, P; Shi, ZZ; Wen, J; Zu, Y | 1 |
| Achtereekte, H; de la Rubia, J; Delgado, J; Douglas, KW; Duarte, RF; Gandhi, PJ; Gayoso, J; Goterriz, R; Kottaridis, P; Marín, P; Martínez-Chamorro, C; Mateos-Mazón, JJ; Morante, C; Ortiz, M; Ramírez, C; Russell, NH; Shaw, BE | 1 |
| Alexander, ET; Costa, LJ; Fouts, TV; Hogan, KR; Schaub, C; Stuart, RK | 1 |
| Jantunen, E; Kuittinen, T; Mahlamäki, E; Nousiainen, T; Penttilä, K; Pyörälä, M | 1 |
| Gatesman, ML; Kessans, MR; Kockler, DR | 1 |
| Calandra, G; Gandhi, PJ; Ho, AD; Klein, LM; Marulkar, S; McSweeney, PA; Micallef, IN | 1 |
| Castelli, A; Conconi, A; Gaidano, G; Pinto, V | 1 |
| Booth, B; Brave, M; Ching Lin, S; Farrell, A; Fourie, J; He, K; Justice, R; Lee, SL; Ocheltree, T; Pazdur, R; Pope Miksinski, S; Saber, H; Tornoe, C; Yuan, W | 1 |
| Agis, H; Baccarani, M; Casadei, B; Curti, A; D'Addio, A; Dan, E; Douglas, K; Giudice, V; Kopetzky, G; Lemoli, RM; Motta, MR; Rizzi, S; Soutar, R; Taioli, S; Worel, N | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T | 1 |
| Silva, M; Steinberg, M | 1 |
| Greinix, HT; Kalhs, P; Kasparu, H; Linkesch, W; Nachbaur, D; Namberger, K; Neumeister, P; Rosskopf, K; Russ, G; Schloegl, E; Witt, V; Worel, N; Zojer, N | 1 |
| Basak, GW; Dabrowska-Iwanicka, A; Dybko, J; Hawrylecka, D; Kisiel, E; Knopinska-Posluszny, W; Matuszak, M; Rzepecki, P; Szmigielska-Kaplon, A; Urbaniak-Kujda, D; Werkun, J; Wiktor-Jedrzejczak, W; Wroblewska, W; Zielinska, P | 1 |
| Albert, MH; Basara, N; Beier, R; Bogner, C; Christopeit, M; Dressler, S; Ebinger, M; Fresen, MM; Frickhofen, N; Galm, O; Hartwig, R; Heits, F; Hertenstein, B; Hübel, K; Kiehl, M; Kröger, N; Lange, F; Liebler, S; Lordick, F; Rösler, W; Salwender, H; Theurich, S; von Lilienfeld-Toal, M; Wehler, D; Weidmann, E; Weigelt, C; Zander, AR | 1 |
| Bruckner, T; Eckstein, V; Hellwig, I; Ho, AD; Saffrich, R; Taubert, I; Wuchter, P; Zepeda-Moreno, A | 1 |
| Damon, LE | 1 |
| Armistead, PM; Gregory, KM; Rao, KV | 1 |
| Bolwell, BJ; Bridger, G; DiPersio, JF; Hsu, FJ; Marulkar, S; Maziarz, RT; Micallef, I; Nademanee, AP; Stadtmauer, EA; Stiff, PJ | 1 |
| Abraham, M; Begin, M; Beider, K; Eizenberg, O; Engelhard, D; Galun, E; Hardan, I; Nagler, A; Peled, A; Pikarsky, E; Wald, H; Wald, O; Weiss, ID; Zeira, E | 1 |
| Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M | 1 |
| Fruehauf, S; Jantunen, E | 1 |
| Bokhari, SW; Cook, G; D'Addio, A; Douglas, KW; Hayden, PJ; Lemoli, RM; Maris, M; Masszi, T; Mikala, G; Noppeney, R; Pagliuca, A; Parker, AN; Rahemtulla, A; Rao, K; Scheid, C; Taylor, R; Treisman, J; Uberti, J; Worel, N | 1 |
| Basak, GW; Basic-Kinda, S; Giebel, S; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Anderson, D; Flowers, CR; Gleason, C; Graiser, M; Hamilton, E; Kaufman, JL; Langston, A; Lechowicz, MJ; Li, J; Lonial, S; Prichard, JM; Renfroe, H; Vaughn, L; Waller, EK | 1 |
| Baker, J; Conkling-Walsh, A; Cooper, DL; Foss, F; Medoff, E; Pratt, K; Seropian, SE; Snyder, E; Yen, W | 1 |
| Basak, GW; Basic-Kinda, S; Cegledi, A; Giebel, S; Hübel, K; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Reti, M; Wiktor-Jedrzejczak, W | 1 |
| Attolico, I; Coluzzi, S; Crescimanno, A; Di Nardo, E; Iacopino, P; Martino, M; Milone, G; Musso, M; Nuccorini, R; Olivieri, A; Ostuni, A; Pascale, S; Pavone, V; Rossini, B; Tedeschi, P | 1 |
| Jantunen, E | 1 |
| Keating, GM | 1 |
| Hata, H | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Mohty, M; Selleslag, D; Wiktor-Jedrzejczak, W; Worel, N | 1 |
| Andreola, G; Babic, A; Laszlo, D; Martinelli, G; Negri, M; Rabascio, C | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Fresen, MM; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, RM; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| DiPersio, JF | 1 |
| Kaufman, J; Mahaseth, H | 1 |
| Bensinger, WI; Gopal, AK; Holmberg, L; Karami, M; Linenberger, M; Macebeo, M; Mayor, J | 1 |
| Jantunen, E; Juutilainen, A; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Varmavuo, V | 1 |
| Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, AL; Shoptaw, KB; Stuart, RK | 1 |
| Abbas, J; Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, A; McDonald, K; Shoptaw, K; Stuart, RK | 1 |
| Akı, SZ; Altuntaş, F; Ayyıldız, E; Baysal, NA; Dönmez, A; Ilhan, O; Sarı, I; Sıvgın, S; Tekgündüz, E; Tombuloğlu, M; Topçuoğlu, P; Unal, A; Yıldırım, R; Yüksel, MK | 1 |
| Bolwell, BJ; Bridger, G; DiPersio, JF; Hsu, FJ; Maziarz, RT; Micallef, IN; Nademanee, AP; Stadtmauer, EA; Stiff, PJ | 1 |
| Aoun, C; Brignier, AC; Cavazzana-Calvo, M; Dal Cortivo, L; Larghéro, J; Lefrère, F; Mauge, L; Micléa, JM; Réa, D; Ribeil, JA | 1 |
| Ball, ED; Belew, H; Helmons, PJ; Lane, JR; Lor, KW | 1 |
| Calandra, G; Gandhi, PJ; Jacobsen, ED; Micallef, IN; Shaughnessy, P; Uberti, J; van Rhee, F | 1 |
| Devine, SM | 1 |
| Jantunen, E; Kuittinen, T; Mäntymaa, P; Nousiainen, T; Silvennoinen, R; Varmavuo, V | 1 |
| Carlson, K; Chabannon, C; Douglas, K; Ho, AD; Milone, G; Mohty, M; Ossenkoppele, GJ; Pareja, MO; Russell, N; Shaheen, D; Whitaker, N; Willemsen, A | 1 |
| Artz, A; Ball, ED; Berryman, R; Devine, S; Dugan, M; Hsu, FJ; Jacobsen, E; Johns, D; Joyce, R; Maziarz, RT; McCarty, J; McSweeney, P; Micallef, I; Shaughnessy, P; Stiff, P; Uberti, J; Vose, J | 1 |
| Badel, K; Calandra, G; Devine, SM; DiPersio, JF; Flomenberg, N; Liesveld, J; Vesole, DH; Weisdorf, D | 1 |
| Aglietta, M; Carnevale Schianca, F; Cavalloni, G; Grignani, G; Perissinotto, E | 1 |
| Calandra, G; DiPersio, J; Flomenberg, N | 1 |
| Alsayed, Y; Anderson, KC; Côté, D; Ghobrial, IM; Ghobrial, JM; Hedin, KE; Hideshima, T; Jia, X; Kimlinger, T; Kumar, A; Kung, AL; Leleu, X; Lin, CP; Lu, G; Ngo, H; Pitsillides, CM; Roodman, GD; Runnels, J; Singha, UK; Spencer, JA; Timm, M; Veilleux, I; Witzig, TE | 1 |
| Bornhauser, M; Boxberger, S; Calandra, G; Ehninger, G; Hoelig, K; Illmer, T; Kroschinsky, F; Oelschlaegel, U; Platzbecker, U | 1 |
18 review(s) available for plerixafor and Multiple Myeloma
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
Topics: Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Multiple Myeloma; Risk Factors; Stem Cell Niche; Transplantation, Autologous | 2019 |
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Topics: Benzylamines; Cyclams; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Transplantation, Autologous | 2014 |
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Topics: Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous | 2015 |
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Premedication; Treatment Outcome | 2016 |
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; HIV; Humans; Lymphoma, Non-Hodgkin; Molecular Sequence Data; Multiple Myeloma; Protein Conformation; Receptors, CXCR4; Virus Internalization | 2009 |
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Infusions, Subcutaneous; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2009 |
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma | 2009 |
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation | 2010 |
Plerixafor: a peripheral blood stem cell mobilizer.
Topics: Animals; Benzylamines; Bone Marrow; Chemokine CXCL12; Contraindications; Cyclams; Drug Interactions; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Off-Label Use; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Salvage Therapy | 2010 |
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Topics: Animals; Antineoplastic Agents; Benzylamines; Cyclams; Cyclophosphamide; Economics, Pharmaceutical; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2010 |
Mobilization of hematopoietic stem cells into the peripheral blood.
Topics: Animals; Anti-HIV Agents; Benzylamines; Bone Marrow; Chemokine CXCL12; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Mice; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4 | 2009 |
Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
Topics: Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2011 |
Novel strategies for blood stem cell mobilization: special focus on plerixafor.
Topics: Animals; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia; Lymphoma; Multiple Myeloma; Stem Cell Transplantation | 2011 |
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Topics: Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma | 2011 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Optimizing stem cell collection through CXCR4 antagonists.
Topics: Animals; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4 | 2012 |
Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.
Topics: Anti-HIV Agents; Benzylamines; Bone Marrow; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Clinical Trials as Topic; Cyclams; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Protein Binding; Receptors, CXCR4; Recombinant Proteins; Transplantation, Autologous | 2005 |
35 trial(s) available for plerixafor and Multiple Myeloma
| Article | Year |
|---|---|
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Bone Marrow; Bortezomib; Combined Modality Therapy; Cyclams; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Receptors, CXCR4; Recurrence; Salvage Therapy; Tumor Microenvironment | 2019 |
Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Proof of Concept Study; Transplantation, Autologous | 2019 |
Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
Topics: Adult; Aged; Autografts; Benzylamines; Cyclams; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Recovery of Function | 2020 |
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Topics: Adolescent; Adult; Aged; Benzylamines; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Longitudinal Studies; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Topics: Adult; Aged; Autografts; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating | 2019 |
A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma.
Topics: Administration, Intravenous; Adult; Aged; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Treatment Outcome | 2014 |
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Topics: Adult; Aged; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Treatment Outcome | 2013 |
Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers.
Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Topics: Administration, Intravenous; Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
Topics: Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Benzylamines; Cyclams; Drug Synergism; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Topics: Adult; Anti-HIV Agents; Autografts; Benzylamines; Blood Component Removal; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins | 2014 |
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor.
Topics: Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Blood Component Removal; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2014 |
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Retrospective Studies | 2015 |
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Risk Factors | 2015 |
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma | 2014 |
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cyclophosphamide; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Vincristine | 2015 |
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Topics: Adult; Aged; Benzylamines; Blood Cell Count; Blood Component Removal; Bone Marrow; Combined Modality Therapy; Costs and Cost Analysis; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies | 2016 |
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Pharmacokinetics; Receptors, CXCR4; Transplantation, Autologous | 2009 |
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cell Count; Cyclams; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4 | 2009 |
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adolescent; Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2009 |
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antiviral Agents; Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects | 2010 |
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polymerase Chain Reaction; Treatment Outcome | 2010 |
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kinetics; Male; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous; Young Adult | 2010 |
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experienc
Topics: Adolescent; Adult; Aged; Antigens, CD34; Austria; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunoglobulin G; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous; Young Adult | 2011 |
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Child; Child, Preschool; Combined Modality Therapy; Compassionate Use Trials; Cyclams; Female; Germany; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult | 2011 |
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Blood Platelets; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Platelet Count; Survival Analysis; Transplantation, Autologous | 2011 |
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recovery of Function; Transplantation, Autologous | 2012 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Child; Cyclams; European Union; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Homologous | 2012 |
Plerixafor use in patients with previous mobilization failure: A multicenter experience.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Biomarkers; Blood Component Removal; Cyclams; Double-Blind Method; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunologic Factors; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Placebos; Receptors, CXCR4; Transplantation, Autologous | 2012 |
A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Cells; Blood Component Removal; Cyclams; Drug Administration Schedule; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Time Factors; Treatment Failure | 2013 |
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2013 |
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Time Factors; Transplantation, Autologous; United States | 2013 |
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Statistics, Nonparametric | 2004 |
94 other study(ies) available for plerixafor and Multiple Myeloma
| Article | Year |
|---|---|
Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma.
Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Humans; Middle Aged; Multiple Myeloma; Renal Dialysis | 2021 |
Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
Topics: Antigens, CD34; Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Blood Stem Cells; Retrospective Studies; Transplantation, Autologous | 2022 |
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
Topics: Adult; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Topics: Anti-Bacterial Agents; Antigens, CD34; Benzylamines; Cyclams; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Topics: Benzylamines; COVID-19; Cyclams; Cyclophosphamide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Multiple Myeloma; Pandemics; Retrospective Studies; Transplantation, Autologous | 2022 |
MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
Topics: Benzylamines; Blood Component Removal; Cost-Benefit Analysis; Cyclams; Delivery of Health Care; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Japan; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Registries | 2020 |
Impact of Plerixafor Use at Different Peripheral Blood CD34
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Transplantation, Autologous | 2020 |
Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
Topics: Adult; Aged; Benzylamines; Biomarkers; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Retrospective Studies; Transplantation, Autologous | 2020 |
Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
Topics: Animals; Antigens, CD34; Benzylamines; Child; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Mice; Middle Aged; Multiple Myeloma; Stem Cells | 2020 |
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.
Topics: Anemia, Sickle Cell; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Blood Stem Cells; Transplantation, Autologous | 2020 |
Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Japan; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cells; Transplantation, Autologous | 2021 |
[Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].
Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Plasma Cells; Retrospective Studies; Transplantation, Autologous | 2021 |
Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.
Topics: Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2017 |
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Topics: Benzylamines; Biosimilar Pharmaceuticals; Blood Cell Count; Cyclams; Filgrastim; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Propensity Score; Retrospective Studies | 2017 |
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aptamers, Nucleotide; Benzylamines; Biomarkers; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Chromosome Aberrations; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Immunophenotyping; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Phosphorylation; Protein Multimerization; Protein Transport; Receptors, CXCR; Stromal Cells | 2017 |
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
Topics: Benzylamines; Cell Count; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2018 |
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Topics: Adult; Age Factors; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prospective Studies; Transplantation, Autologous; Young Adult | 2018 |
Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma.
Topics: Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation | 2018 |
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
Topics: Adult; Aged; Autografts; Benzylamines; Chemotherapy, Adjuvant; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Induction Chemotherapy; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Regression Analysis; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2019 |
Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Topics: Adult; Benzylamines; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2013 |
Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy | 2013 |
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Leukocytes, Mononuclear; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Time Factors; Transplantation, Autologous; Young Adult | 2014 |
GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
Topics: Adult; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Retrospective Studies; Young Adult | 2014 |
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Chemoradiotherapy; Cyclams; Data Collection; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Italy; Leukapheresis; Lymphoma; Male; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Receptors, CXCR4; Young Adult | 2014 |
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclams; Double-Blind Method; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Neutropenia; Pain; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2013 |
Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Topics: Adolescent; Adult; Aged; Benzylamines; Child; Child, Preschool; Cost-Benefit Analysis; Cyclams; Cytapheresis; Czechoslovakia; Decision Trees; Female; Granulocyte Colony-Stimulating Factor; Health Expenditures; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Infant; Length of Stay; Lymphoma; Male; Middle Aged; Models, Economic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Treatment Outcome; Young Adult | 2013 |
Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Topics: Antigens, CD34; Benzylamines; Cohort Studies; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, CXCR4; Time Factors | 2014 |
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Retrospective Studies; Young Adult | 2014 |
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Topics: Benzylamines; Boronic Acids; Bortezomib; Chemokine CXCL12; Computer Simulation; Cyclams; Drug Delivery Systems; Drug Synergism; Heterocyclic Compounds; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Multiple Myeloma; Neoplastic Stem Cells; Paracrine Communication; Pyrazines; Tumor Microenvironment | 2014 |
Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Combined Modality Therapy; Costs and Cost Analysis; Cyclams; Cyclophosphamide; Drug Evaluation; Drug Synergism; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukapheresis; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2014 |
Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Economics, Pharmaceutical; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2014 |
Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.
Topics: Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2014 |
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Incidence; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Transplantation, Autologous | 2014 |
Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
Topics: Adult; Aged; Belgium; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prospective Studies; Transplantation, Autologous | 2015 |
Plerixafor: what we still have to learn.
Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Obesity; Overweight; Patient Selection; Transplantation, Autologous | 2015 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria.
Topics: Adult; Algeria; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Stem Cell Transplantation; Young Adult | 2015 |
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Netherlands; Retrospective Studies | 2015 |
G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
Topics: Adult; Aged; Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lebanon; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2015 |
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Platelets; Cost-Benefit Analysis; Cyclams; Female; Filgrastim; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Length of Stay; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Plasma Cell; Neutrophils; Retrospective Studies; Transplantation, Autologous | 2015 |
Plerixafor may treat intractable post-herpetic neuralgia.
Topics: Benzylamines; Bone Marrow Cells; Cell Movement; Cyclams; Ganglion Cysts; Herpes Zoster; Heterocyclic Compounds; Humans; Inflammation; Lymphoma, Non-Hodgkin; Models, Theoretical; Multiple Myeloma; Neuralgia; Neuralgia, Postherpetic; Neurons; Spinal Cord; Stem Cell Transplantation; Stem Cells; United States | 2015 |
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
Topics: Benzylamines; Cost-Benefit Analysis; Costs and Cost Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Historically Controlled Study; Humans; Lymphoma; Multiple Myeloma | 2016 |
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cost-Benefit Analysis; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult | 2015 |
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.
Topics: Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Multiple Myeloma | 2016 |
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicent
Topics: Adult; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Prognosis; Republic of Korea; Retrospective Studies; Treatment Failure; Young Adult | 2016 |
[Combination of pegfilgrastim and plerixafor as an effective regimen of hematopoietic stem cells mobilization in cancer patients: own experience].
Topics: Adult; Aged; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins | 2015 |
Autologous Stem Cell Mobilization in the Age of Plerixafor.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Workflow | 2016 |
[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous | 2016 |
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Topics: Autografts; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Blood Stem Cells; Plasma Cells; Retrospective Studies | 2017 |
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Survival; Coculture Techniques; Colony-Forming Units Assay; Cyclams; Drug Resistance, Neoplasm; Fibronectins; Flow Cytometry; Heterocyclic Compounds; Humans; Immunoblotting; Immunoenzyme Techniques; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lentivirus; Male; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Stromal Cells; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Plerixafor.
Topics: Animals; Benzylamines; Cyclams; Drug Approval; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4 | 2009 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Topics: Anti-HIV Agents; Benzylamines; Blood Component Removal; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Multiple Myeloma; Transplantation, Autologous | 2009 |
Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzylamines; Bone Marrow Cells; Case-Control Studies; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cyclams; Heterocyclic Compounds; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2010 |
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Drug Therapy, Combination; European Union; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |
Plerixafor (Mozobil).
Topics: Antineoplastic Agents; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous | 2010 |
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Topics: Algorithms; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cohort Studies; Cost Savings; Cyclams; Decision Support Techniques; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2011 |
Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients.
Topics: Aged; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma | 2011 |
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Topics: Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2011 |
Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Cyclams; Dexamethasone; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kidney Failure, Chronic; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Renal Dialysis; Thalidomide; Transplantation Conditioning | 2010 |
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Clinical Trials as Topic; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Placebos; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Receptors, CXCR4; United States; United States Food and Drug Administration | 2010 |
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 2011 |
Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone.
Topics: Antigens, CD34; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Siblings; Transplantation, Homologous | 2011 |
Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Poland; Receptors, CXCR4; Retrospective Studies; Transplantation, Autologous; Young Adult | 2011 |
Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.
Topics: Benzylamines; Clinical Trials as Topic; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Multiple Myeloma; Receptors, CXCR4 | 2010 |
Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Topics: Aged; Benzylamines; Cells, Cultured; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Polymerase Chain Reaction; Receptors, CXCR4 | 2011 |
Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Topics: Adult; Benzylamines; Combined Modality Therapy; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Multiple Myeloma; Receptors, CXCR4; Renal Dialysis; Renal Insufficiency | 2010 |
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Peptides; Receptors, CXCR4 | 2011 |
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Receptors, CXCR4; Recombinant Proteins; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cyclams; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kidney Transplantation; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Renal Dialysis; Renal Insufficiency; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Recombinant Proteins; Recurrence; Retrospective Studies; Transplantation, Autologous | 2011 |
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cohort Studies; Cost-Benefit Analysis; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Young Adult | 2011 |
Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2011 |
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.
Topics: Adult; Aged; Aged, 80 and over; Benzylamines; Body Mass Index; Contraindications; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Obesity; Overweight; Retrospective Studies; Thinness; Young Adult | 2012 |
Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow Transplantation; Combined Modality Therapy; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
New hope for mobilization failures . . . again.
Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation | 2012 |
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Lymphoma; Middle Aged; Multiple Myeloma | 2012 |
Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Chemoprevention; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kinetics; Leukocyte Count; Leukocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prognosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure | 2012 |
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cost-Benefit Analysis; Cyclams; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2012 |
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Topics: Aged; Algorithms; Antigens, CD34; Benzylamines; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Thalidomide | 2012 |
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Academic Medical Centers; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Transplantation, Autologous | 2012 |
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
Topics: Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Multiple Myeloma; Platelet Count; Retrospective Studies; Thrombocytopenia | 2013 |
Toward a more rational policy for autologous hematopoietic stem cell mobilization.
Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Drug Combinations; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous | 2012 |
CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Biomarkers; Cyclams; Cyclophosphamide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukapheresis; Lymphocyte Subsets; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2013 |
Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2005 |
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Benzylamines; Bone Marrow; Case-Control Studies; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Cyclams; Cytoskeleton; Heterocyclic Compounds; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Receptors, CXCR4 | 2007 |
Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma.
Topics: Benzylamines; Cell Adhesion Molecules; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kinetics; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous | 2007 |
Molecule of the month. Plerixafor hydrochloride.
Topics: Anti-HIV Agents; Benzylamines; Clinical Trials as Topic; Cyclams; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Molecular Structure; Multiple Myeloma; Receptors, CXCR4 | 2007 |